Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Read now
Joel McCay & John G. Gribben. (2022) The role of BTK inhibitors on the tumor microenvironment in CLL. Leukemia & Lymphoma 63:9, pages 2023-2032.
Read now
Read now
James T. England & Heather A. Leitch. (2018) Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib. Leukemia & Lymphoma 59:3, pages 752-754.
Read now
Read now
Articles from other publishers (14)
Alexandre Poirier & Michel L. Tremblay. (2022) Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy. Cancer Immunology, Immunotherapy 72:6, pages 1343-1353.
Crossref
Crossref
Peng-Peng Xu, Zi-Yang Shi, Ying Qian, Shu Cheng, Yue Zhu, Lu Jiang, Jian-Feng Li, Hai Fang, Heng-Ye Huang, Hong-Mei Yi, Bin-Sheng Ouyang, Li Wang & Wei-Li Zhao. (2022) Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study. The Lancet Healthy Longevity 3:7, pages e481-e490.
Crossref
Crossref
Tamara Mateu-Albero, Ana Marcos-Jimenez, Stefanie Wissmann, Javier Loscertales, Fernando Terrón, Jens V. Stein, Cecilia Muñoz-Calleja & Carlos Cuesta-Mateos. (2022) Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients. Cancers 14:11, pages 2729.
Crossref
Crossref
Stefan F. H. Neys, Jasper Rip, Rudi W. Hendriks & Odilia B. J. Corneth. (2021) Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. Drugs 81:14, pages 1605-1626.
Crossref
Crossref
Sining Zhu, Samantha Gokhale, Jaeyong Jung, Eris Spirollari, Jemmie Tsai, Johann Arceo, Ben Wang Wu, Eton Victor & Ping Xie. (2021) Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Justin K. Messex & Geou-Yarh Liou. (2021) Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option. Cancers 13:9, pages 2198.
Crossref
Crossref
Tom A. Mulder, Lucía Peña-Pérez, Anna Berglöf, Stephan Meinke, H. Yesid Estupiñán, Kia Heimersson, Rula Zain, Robert Månsson, C. I. Edvard Smith & Marzia Palma. (2021) Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. HemaSphere 5:5, pages e564.
Crossref
Crossref
Sanjay Varikuti, Chaitenya Verma, Gayathri Natarajan, Steve Oghumu & Abhay R. Satoskar. (2021) MicroRNA155 Plays a Critical Role in the Pathogenesis of Cutaneous Leishmania major Infection by Promoting a Th2 Response and Attenuating Dendritic Cell Activity. The American Journal of Pathology 191:5, pages 809-816.
Crossref
Crossref
Chaja F. Jacobs, Eric Eldering & Arnon P. Kater. (2021) Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances 5:3, pages 913-925.
Crossref
Crossref
Sanjay Varikuti, Bhawana Singh, Greta Volpedo, Dinesh K. Ahirwar, Bijay K. Jha, Noushin Saljoughian, Agostinho G. Viana, Chaitenya Verma, Omar Hamza, Gregory Halsey, Erin A. Holcomb, Ritvik J. Maryala, Steve Oghumu, Ramesh K. Ganju & Abhay R. Satoskar. (2020) Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. British Journal of Cancer 122:7, pages 1005-1013.
Crossref
Crossref
Rossana Maffei, Monica Maccaferri, Laura Arletti, Stefania Fiorcari, Stefania Benatti, Leonardo Potenza, Mario Luppi & Roberto Marasca. (2020) Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. Blood Reviews 40, pages 100635.
Crossref
Crossref
Jean-François Rossi, Patrice Céballos & Zhao-Yang Lu. (2019) Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Communications 39:1, pages 34.
Crossref
Crossref
Tom Hofland, Iris de Weerdt, Hanneke ter Burg, Renate de Boer, Stacey Tannheimer, Sanne H. Tonino, Arnon P. Kater & Eric Eldering. (2019) Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. The Journal of Immunology 203:8, pages 2100-2109.
Crossref
Crossref
Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak & Cornelia Brunner. (2017) Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Frontiers in Immunology 8.
Crossref
Crossref